ScholarIQanswers from OpenAlex
Capgemini (Netherlands)
InstitutionResearch output, impact & collaborations
Capgemini (Netherlands) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Capgemini (Netherlands)?
ScholarIQrecord summary
Capgemini (Netherlands) is a research organisation in Utrecht, NL. OpenAlex records 2,393 works and 25,462 citations for it. 987 researchers list it as their most recent affiliation.
How many works does Capgemini (Netherlands) have?
ScholarIQindexed works
Capgemini (Netherlands) has 2,393 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Capgemini (Netherlands) have?
ScholarIQcitation count
Capgemini (Netherlands) has 25,462 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Capgemini (Netherlands)?
ScholarIQresearcher count
Capgemini (Netherlands) has 987 researchers in the ScholarIQ index.
What is the average h-index at Capgemini (Netherlands)?
ScholarIQavg h-index
Capgemini (Netherlands) has an average h-index of 43 in OpenAlex.
What is the ROR of Capgemini (Netherlands)?
ScholarIQror
The ROR for Capgemini (Netherlands) is on the source record.
What is the OpenAlex record for Capgemini (Netherlands)?
ScholarIQopenalex
The OpenAlex for Capgemini (Netherlands) is on the source record.
What is the Wikidata of Capgemini (Netherlands)?
ScholarIQwikidata
The Wikidata for Capgemini (Netherlands) is on the source record.
Who are the most-cited researchers behind Capgemini (Netherlands)?
ScholarIQtop researchers by citations
What are the most-cited papers on Capgemini (Netherlands)?
ScholarIQmost cited works
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
Kimberly H. Allison, M. Elizabeth H. Hammond, Mitch Dowsett, Shannon McKernin, Lisa A. Carey, Patrick L. Fitzgibbons, Daniel F. Hayes, Sunil R. Lakhani, Mariana Chávez‐MacGregor, Jane Perlmutter, Charles M. Perou, Meredith M. Regan, David L. Rimm, W. Fraser Symmans, Emina Torlakovic, Leticia Varella, Giuseppe Viale, Tracey Weisberg, Lisa M. McShane, Antonio C. Wolff
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne M. Wallace, A. Jo Chien, Andres Forero‐Torres, Erin D. Ellis, Heather Han, Amy S. Clark, Kathy S. Albain, Judy C. Boughey, Nora Jaskowiak, Anthony Elias, Claudine Isaacs, Kathleen Kemmer, Teresa Helsten, Melanie Majure, Erica Stringer-Reasor, Catherine Parker, Marie Catherine Lee, Tufia C. Haddad, Ronald Cohen, Smita Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam L. Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Richard B. Schwab, W. Fraser Symmans, Laura van ‘t Veer, Douglas Yee, Angela DeMichele, Nola M. Hylton, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Donald A. Berry, Laura J. Esserman
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Hope S. Rugo, Olufunmilayo I. Olopade, Angela DeMichele, Christina Yau, Laura van ‘t Veer, Meredith Buxton, Michael Hogarth, Nola M. Hylton, Melissa Paoloni, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, A. Jo Chien, Anne M. Wallace, Henry G. Kaplan, Judy C. Boughey, Tufia C. Haddad, Kathy S. Albain, Minetta C. Liu, Claudine Isaacs, Qamar J. Khan, Julie E. Lang, Rebecca K. Viscusi, Lajos Pusztai, Stacy L. Moulder, Jane Yuet Ching Hui, Kathleen Kemmer, Anthony Elias, Kirsten K. Edmiston, David Euhus, Barbara Haley, Rita Nanda, Donald W. Northfelt, Debasish Tripathy, William C. Wood, Cheryl A. Ewing, Richard B. Schwab, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Donald A. Berry, Laura J. Esserman
Adaptive Randomization of Neratinib in Early Breast Cancer
John W. Park, Minetta C. Liu, Douglas Yee, Christina Yau, Laura van ‘t Veer, W. Fraser Symmans, Melissa Paoloni, Jane Perlmutter, Nola M. Hylton, Michael Hogarth, Angela DeMichele, Meredith Buxton, A. Jo Chien, Anne M. Wallace, Judy C. Boughey, Tufia C. Haddad, Jane Yuet Ching Hui, Kathleen Kemmer, Henry G. Kaplan, Claudine Isaacs, Rita Nanda, Debasish Tripathy, Kathy S. Albain, Kirsten K. Edmiston, Anthony Elias, Donald W. Northfelt, Lajos Pusztai, Stacy L. Moulder, Julie E. Lang, Rebecca K. Viscusi, David Euhus, Barbara Haley, Qamar J. Khan, William C. Wood, Michelle Melisko, Richard B. Schwab, Teresa Helsten, Julia Lyandres, Sarah Davis, Gillian L. Hirst, Ashish Sanil, Laura J. Esserman, Donald A. Berry
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace, Erica String-Reasor, Judy C. Boughey, A. Jo Chien, Anthony Elias, Heather Beckwith, Rita Nanda, Kathy S. Albain, Amy S. Clark, Kathleen Kemmer, Kevin Kalinsky, Claudine Isaacs, Alexandra Thomas, Rebecca Shatsky, Theresa L. Helsten, Andres Forero‐Torres, Minetta C. Liu, Lamorna Brown Swigart, Emmanuel Petricoin, Julia Wulfkuhle, Smita Asare, Amy Wilson, Ruby Singhrao, Laura Sit, Gillian L. Hirst, Scott Berry, Ashish Sanil, Adam L. Asare, Jeffrey B. Matthews, Jane Perlmutter, Michelle Melisko, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Douglas Yee, Laura J. van’t Veer, Nola M. Hylton, Angela DeMichele, Donald A. Berry, Laura J. Esserman
How much of the research on Capgemini (Netherlands) is open access?
ScholarIQopen access share
88%OPEN ACCESS